TABLE 1
Chemical structure of haptens, the resulting mAb, KD values for key drugs, and in vivo testing performed
Hapten Structure and Abbreviated Name | mAb Name (Isotype and Light Chain Type) | Key Psychostimulant | Preclinical Testinga | ||||
|---|---|---|---|---|---|---|---|
| (+)-METH KD | (+)-AMP KD | (+)-MDMA KD | |||||
| nM | |||||||
| Anti-METH/MDMA mAb6H8 (IgG1 κ) | 250 | 41,000 | 106 | SA4, DD3 L1,5, M-PCKN, mAb-PCKN | ||
| Anti-METH/MDMA mAb6H4 (IgG1 κ) | 11 | 4000 | 4 | L1,5, SA4, M-PCKN1,2 mAb-PCKN, CV6 | ||
| Anti-METH/MDMA mAb6H7 (IgG2b κ) | 95 | 47,000 | 87 | M-PCKN, mAb-PCKN, CV, DD, SA | ||
| Anti-METH/MDMA mAb9B11 (IgG1 λ) | 41 | 5000 | 123 | M-PCKN, SA | ||
| Anti-METH/MDMA/AMP mAb4G9 (IgG2b κ) | 34 | 120 (51 nM with [(+)-3H]AMP) | 140 | M-PCKN, mAb-PCKN, DD, SA | ||
-
CV, cardiovascular; DD, drug discrimination; L, locomotor; mAb-PCKN, antibody pharmacokinetics; M-PCKN, METH pharmacokinetics; and SA, self-administration.
-
↵ a The superscript numbers after abbreviations refer to the following references: 1 Byrnes-Blake et al. (2003); 2 Laurenzana et al. (2003); 3 McMillan et al. (2002); 4 McMillan et al. (2004); 5 Byrnes-Blake et al. (2005); and 6 Gentry et al. (2006). No reference indicates manuscript is in preparation.